



Genzyme Corporation is conducting a **global phase 2 study** to further understand the effect Rabbit Antithymocyte Globulin (rATG) has on MDS.

Title: A Phase II Study of Efficacy of Rabbit Anti-thymocyte Globulin (rATG) in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome

Population: Adult patients 70 years of age or younger with low and intermediate-1 IPSS risk MDS who have received no more than 1 prior treatment.

Primary Objective: Hematologic Improvement rate during the 12 month study period with rATG, as defined by the 2006 International Working Group response criteria.

Status: This study is currently recruiting patients.

Location: France, Germany, The Netherlands, United Kingdom, United States

Contact: Genzyme Medical Information
Tel: 800-745-4447 Option 2
Tel: (International): 617-768-9000
Fax: 617-591-7178
E-mail: medinfo@genzyme.com

Website: <http://www.clinicaltrials.gov> (identifier # NCT00542828)

Study Contact Information:

Prof. Pierre Fenaux
Hôpital Avicene/University
Paris, France
+33 1 48 95 70 51

Prof. Bruno Quesnel
Hôpital Huriev
Lille, France
+33 320 446 640

Prof. Arnold Ganser
Medizinische Hochschule
Hannover (Hanover Medical School)
Hannover, Germany
+49 511 532 3020

Dr. Aristoteles Giagounidis
St. Johannes-Hospital Duisburg
Duisburg, Germany
+49 203 546 2249

Dr. Sally Killick
Royal Bournemouth Hospital
Bournemouth, UK
+44 1202 303 636

Prof. Ghulam J. Mufti
King's College Hospital
London, UK
+44 20 3299 3080

Dr. David Bowen
St. James Hospital
Leeds, UK
+44 113 206 8465

Dr. Petra Muus
UMC St. Radboud Centraal
Nijmegen, The Netherlands
+31 24 361 8810

Dr. John McCarty
Virginia Commonwealth University
Richmond, VA
USA
1 (804) 828-4732 (Kathly Candler)

Dr. Jamile Shammo
RUSH University Medical Center
Chicago, IL
USA
1 (312) 563-2330 (Darilyn Rhoades)